Healthcare Services

An Important Factor Driving the Alzheimer’s Disease Diagnostic Market Global Report 2026 Market Is the Impact Of Chronic Disease Growth On Alzheimer’s Disease Diagnostic Industry

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Alzheimer’s Disease Diagnostic Market Over The 2026–2030 Period?

In recent years, the size of the alzheimer’s disease diagnostic market has experienced rapid expansion. It is projected to expand from $7.26 billion in 2025 to $8.03 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.6%. Historically, this expansion has stemmed from factors such as the increasing prevalence of alzheimer’s disease, greater public awareness of neurodegenerative disorders, the integration of MRI and PET imaging techniques, the proliferation of diagnostic centers and hospitals, and enhanced investment in cognitive assessment research.

The alzheimer’s disease diagnostic market is projected to undergo significant expansion in the coming years, with its size expected to reach $11.89 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is propelled by factors such as the development of novel biomarkers and imaging tracers, the integration of artificial intelligence for early diagnosis, a surge in government and private funding for alzheimer’s research, the expansion of personalized medicine initiatives, and an increase in multi-center clinical trials. Noteworthy trends predicted for this period include the rising adoption of biomarker-based diagnostics, increased utilization of neuroimaging techniques for early detection, a growth in cognitive assessment testing, the expansion of genetic testing for alzheimer’s risk assessment, and the integration of multi-modal diagnostic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What Underlying Factors Are Accelerating The Growth Of The Alzheimer’s Disease Diagnostic Market?

The projected expansion of the Alzheimer’s disease diagnostic market is anticipated due to the rising prevalence of chronic conditions. Conditions like cardiovascular disease, diabetes, and hypertension are closely linked to an elevated likelihood of developing Alzheimer’s and other dementias, consequently stimulating the need for prompt and precise diagnostic tools. A primary contributor to the increase in chronic diseases stems from the widespread adoption of sedentary lifestyles, given that extensive epidemiological studies consistently demonstrate considerably higher occurrences of conditions like diabetes and cardiovascular disease among individuals with low physical activity. Alzheimer’s diagnostics assist healthcare systems by facilitating early detection, allowing for prompt interventions, and directing patient care to decelerate the progression of the disease. As an illustration, data from November 2023, provided by Heritage Health Services, a US-based nonprofit organization dedicated to healthcare research, indicated that 6.7 million Americans aged 65 or older suffered from Alzheimer’s dementia, with its prevalence escalating with age: 5.0% for 65–74 years, 13.1% for 75–84 years, and 33.3% for 85+ years. Projections suggest this figure will climb to nearly 13 million by 2050. Consequently, the growing incidence of chronic conditions is fueling the expansion of the Alzheimer’s disease diagnostic market.

How Is The Alzheimer’s Disease Diagnostic Market Segmented Across Key Categories?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Which Upcoming Trends Are Expected To Influence The Alzheimer’s Disease Diagnostic Market?

Leading companies operating within the Alzheimer’s disease diagnostic market are concentrating on advancements in blood-based biomarker tests. This focus is anticipated to streamline the diagnostic process for Alzheimer’s disease, lessening the dependence on more intrusive procedures and enhancing patients’ access to timely treatment. For instance, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, a biomarker for Alzheimer’s pathology that demonstrates clinical sensitivity and specificity in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, including positron emission tomography (PET) or lumbar puncture, are both costly, invasive, and not broadly accessible. Additionally, this test combines Quanterix’s ultra-sensitive Simoa® technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, leading to excellent accuracy and a simpler process.

Who Are The Dominant Players Shaping The Alzheimer’s Disease Diagnostic Market Landscape?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Read the full alzheimer’s disease diagnostic market report here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Region Is Projected To Dominate The Alzheimer’s Disease Diagnostic Market During The Forecast Period?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Alzheimer’s Disease Diagnostic Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

alzheimers drugs global market report

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

neurological biomarkers global market report

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

autism spectrum disorder diagnostics global market report

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795